1,721,041 research outputs found
Metabolic syndrome and its components in postmenopausal women living in southern Italy, Apulia region.
No full textObjectives
The goal of our study was to determine the prevalence of metabolic syndrome (MetS) and all its components, in a population of postmenopausal women aged over 45 years, consecutively accessed to our Heart Station, during 2014, for their first cardiac examination,furthermore to estimate their cardiovascular risk and the achievement of target blood values of main risk factors, according to current Guidelines.
MethodsWe screened 1257 postmenopausal women. MetS was assessed according to the National-Cholesterol-Education-Program-Adult-Treatment-Panel III definition. Cardiovascular risk was calculated by the Systematic Coronary Risk Evaluation (<65 years).
Results
MetS was assessed on 834 women (66.4%). Prevalence of each component was: hypertension on 767 women (91.9%), central obesity 758 women (90.9%), low high-density lipoproteins cholesterol (HDLc) increased levels 612 women (73.3%), high triglyceride levels 428 women (51.3%), glucose levels higher than 110 mg/dl or diabetes 404 women (48.5%). Cardiovascular risk was moderate until 65 years, but it increases after. Metabolic control in postmenopausal women was poor for glucose, only 82 women (9.8%) presented glucose levels lower than 110 mg/dl, it was better for systolic blood pressure, that was normal in 564 women (67.6%) and worse for lipid levels.
Conclusion
The prevalence of metabolic syndrome in our population of postmenopausal women is high. Hypertension and central obesity are the more common components. The cardiovascular risk is moderate-high, the achievement of target values for glycemic and lipid levels is unsatisfactory, while systolic blood pressure is enough well controlled but however it is mandatory to improve this goal. An early MetS diagnosis and an early educational intervention are useful to decrease cardiovascular risk of postmenopausal women affected by metabolic syndrom
Hypertensive Cardiomyopathy in asymptomatic patients: a neglected diagnosis
No full textHypertensive Cardiomyopathy diagnosis includes different clinical conditions, on asymptomatic patients, assessed by LV changes in geometry, mass and function, i.e. concentric remodeling, concentric or eccentric hypertrophy and filling impairment or early stage of diastolic dysfunction. Often LA is involved and increases its volume and undergoes to geometrical remodeling. Sometimes it occurs clinical heart failure, the patients became symptomatic, with either a preserved or a reduced LVEF. There is considerable variability in the progression from hypertension to Hypertensive Cardiomyopathy, according to differences in the pressure or volume load and to underlying neurohormonal status; but these differences in LV geometry probably are influenced on genetic basis too. A better comprehension of the mechanisms underlying the development of Hypertensive Cardiomyopathy on hypertensive patients will help to prevent among them the onset of cardiovascular events
How Aortic Stiffness in Postmenopausal Women Is Related to Common Cardiovascular Risk Factors
Full text linkObjective. Our study investigates major common cardiovascular risk factors relation with aortic stiffness on 269 postmenopausal women by global pulse wave velocity (PWVg), useful to relate PWVg to risk of major cardiovascular events. Patients and Methods. Women were categorized as hypertensive (H), hypercholesterolemic (C), or diabetic (D). Aortic stiffness was assessed by PWVg measured with pulsed Doppler, at the left ventricular outflow tract (LVOT) and at the right common femoral artery. Results. All population mean PWVg was 8.2 m/s. 85 (26.5%) women were H; mean PWVg was 7.9 m/s. HC women were 118 (36.7%), with mean PWVg 8.3 m/s. HD women were 30 (9.5%), with mean PWVg 7.8 m/s. HDC women were 36 (11.2%), with mean PWVg 9.3 m/s. 52 (16.1%) menstruate women without risk factor were control group (CG), with mean PWVg 6.5 m/s. Highly significant was the statistical difference in PWVg between HDC women and each other group: P<0.0005 versus CG; P<0.01 versus H; P<0.03 versus HC, and P<0.05 versus HD. No difference in PWG was observed comparing the other groups. There was difference for age among all groups, except for CG, made by younger women. Conclusion. PWVg was highly increased in postmenopausal women affected by hypertension, diabetes, and hypercholesterolemia all at once. Hypertension is the major determinant for PWVg. The only addition of diabetes or hypercholesterolemia did not increase significantly PWVg. Our study supports the usefulness of the assessment of aortic stiffness as a marker of cardiovascular disease
Hereditary Juvenile Haemochromatosis and Idiopathic Dilated Cardiomyopathy
No full textHereditary hemochromatosis (HH), a common autosomal recessive disease, is characterized by excessive iron overload/toxicity in multiple organs (joints, liver, heart, pancreas, pituitary, adrenals and skin). Symptoms and signs depend upon the location of the excess iron deposition. Dilated cardiomyopathy is a typical complication of HH. Juvenile haemochromatosis is a rare disorder of iron metabolism with clinical manifestations before 30 years of age. Two common mutations of the haemochromatosis associated gene (HFE), cys282tyr (C282Y) and his63asp (H63D), have been implicated in the HH. These genes also appear to be modulators in cardiovascular disease. In fact the HFE gene defects are related to idiopathic dilated cardiomyopathy (IDCM) in some patients, even though the results of genotype analyses were conflicting. In this case report we investigate a 21 year-old male patient affected by juvenile haemochromatosis associated with heterozygosity for the H63D mutation with an idiopathic dilated cardiomyopathy
Chest pain and palpitations in postmenopausal women with mitral valve prolapse, is there a gastroesophageal origin?
No full textmitral valve prolapse(MVP) is a common disease in women, causing chest pain and palpitation, due to structural and functional valve abnormality, sometime associated with gastro-esophageal-reflux-disease(GERD).This is a challenging clinical problem in clinical practice,requires targeted diagnostic assessment,to identify the underlying causes of the symptoms because treatment needs to be tailored,according to the causes themselves, to resolve the symptoms. Our aim is to assess the prevalence of GERD in a population of postmenopausal women affected by MVP and if there is any correlation between the two conditions
Effect of CPAP on cardiovascular risks in OSA patients. A 4-year follow-up, preliminary data.
No full textno abstrac
TO BLEED OR NOT TO BLEED: THAT IS THE QUESTION. THE SIDE EFFECTS OF APIXABAN.
No full textApixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), as like dabigatran, rivaroxaban, edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleedings, however they can cause bleedings by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risks managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban
Pulmonary hypertension in thyroid diseases.
No full textThe influence of thyroid hormones on cardiovascular system is well established. Thyroid diseases can effectively enhance the alteration on cardiovascular system by influencing chronotropic and inotropic actions of the heart; altering the strength and the speed of contraction, the speed of relaxation, the duration of the potential of action, and the duration of the refractory period and atrio-ventricular conduction time; modulating circulation and peripheral vascular beds. One of the more intriguing insights in the connection between thyroid diseases and cardiovascular alterations is related to the evaluation of the influence of thyroid hormones on pulmonary vascular beds. Literature reported several studies regarding the association between both hypothyroidism and hyperthyroidism and the occurrence of increased vascular pulmonary arterial pressure. Nevertheless, the pathogenetic mechanisms able to explain such relationship are not fully understood. Many doubts still persist in the comprehension of the mechanisms of pulmonary hypertension in thyroid diseases. The aim of this review was to provide possible explanation about the possible interaction between pulmonary vascular beds and thyroid function in order to evaluate the possibility of novel perspectives in the general management of patients suffering from thyroid and cardiovascular diseases
Rosuvastatin: Beyond the cholesterol-lowering effect.
No full textRosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other molecules of the same class, it shows high efficacy in the improvement of lipid profile, and, thanks to its non-cholesterol-lowering actions (anti-inflammatory, antioxidant and antithrombotic), represents a crucial tool for cardiovascular primary and secondary prevention. Moreover, recent data highlight rosuvastatin beneficial effects in several other fields. In this manuscript we analyzed literature sources in order to better define rosuvastatin features and discuss some critical issues.
Copyright © 2016 Elsevier Ltd. All rights reserved
- …
